[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2862
1. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.
  • BACKGROUND: The purpose of this study is to evaluate perioperative morbidity, mortality and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.
  • METHODS: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


2. Rebai W, Fterich F, Makni A, Ksantini R, Bedioui H, Daghfous A, Chebbi F, Jouini M, Ammous A, Kacem M, Ben Safta Z: [Early gastric adenocarcinoma]. Tunis Med; 2010 Jan;88(1):1-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early gastric adenocarcinoma].
  • [Transliterated title] Adénocarcinome superficiel de l'estomac.
  • AIM: the purpose of this study was to determine the epidemiological and clinical behaviour of the superficial adenocarcinoma of the stomach, to clarify its pathological characteristics, its therapy and prognosis.
  • METHODS: Over a period of 14 years (1990-2004), 16 patients were operated for a superficial gastric adenocarcinoma among 155 gastric cancers treated during the same period in the service of general surgery "A" La Rabta.
  • RESULTS: The superficial gastric adenocarcinoma represented 10.3% of our series.
  • Two patients were followed for a chronic stomach ulcer, a patient is followed for Biermer anaemia and another one for Menetrier disease.
  • The cancer was located in the antrum in 8 cases and was multifocal in 3 cases.
  • CONCLUSION: the superficial gastric adenocarcinoma is rare.
  • The follow up of precancerous states allows its diagnosis.
  • The treatment is based on the gastric resection associated to the D1-type lymph node clearance.
  • The multifocal character imposes a surveillance of the remaining gastric stump.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prognosis. Pyloric Antrum / pathology. Retrospective Studies. Survival Rate. Treatment Outcome. Tunisia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415204.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


3. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ: Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol; 2005 Jul;58(7):722-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
  • BACKGROUND: It is sometimes difficult to distinguish between cardia cancer and oesophageal cancer.
  • METHODS: Consecutive patients with a malignant tumour in the oesophagus or stomach were recruited.
  • RESULTS: Endoscopically located adenocarcinoma of the oesophagus was present in 84 patients (64 men, 20 women; mean age, 68 years; range, 44-91).
  • Cancer located primarily in the gastric cardia was present in 63 patients (42 men, 21 women; mean age, 68 years; range, 42-88).
  • The histological diagnosis was metastasis from a primary tumour outside the oesophagus or stomach in 19 patients.
  • Patients in group A had definite oesophageal cancer, group B patients had a definite carcinoma located in the gastric cardia, and group C patients had an obstructing tumour distal in the oesophagus at the level of the diaphragm, which could not be passed with the endoscope.
  • CONCLUSION: CK phenotyping cannot distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cardia. Esophageal Neoplasms / diagnosis. Keratins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):445-54 [11962749.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Neth J Med. 2003 Jan;61(1):14-8 [12688564.001]
  • [Cites] Histopathology. 2003 Aug;43(2):127-34 [12877727.001]
  • [Cites] Pathol Res Pract. 2003;199(9):581-7 [14621193.001]
  • [Cites] Histopathology. 2003 Nov;43(5):453-61 [14636271.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):371-6 [15017595.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):487-94 [9309399.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):820-31 [11857318.001]
  • (PMID = 15976339.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770716
  •  go-up   go-down


Advertisement
4. Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, Menarguez-Pina F, Ruiz-Maciá JA, Morcillo MA: Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol; 2009;6:13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report.
  • Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to hepatocellular carcinoma.
  • Hepatoid adenocarcinoma of the stomach is a cancer with an extremely poor prognosis with few cases reported.
  • Gastric biopsies of the tumor revealed poorly differenciated adenocarcinoma, with hepatoid differentiation.
  • After a diagnosis of AFP-producing hepatoid adenocarcinoma of the stomach with multiple liver metastases was made, pallitive total gastrectomy, without liver resection, was performed.
  • Accurate diagnosis of hepatoid adenocarcinoma of the stomach is important, and should be suspected under certain circumstances.
  • We describe this rare case of hepatoid adenocarcinoma of the stomach, and review the literature concerning the clinicopathological aspects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Jan;30(1):21-7 [16369718.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] J Surg Oncol. 1998 Sep;69(1):41-4 [9762890.001]
  • [Cites] J Urol. 1994 Sep;152(3):958-60 [7519684.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):293-6 [7678544.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Ann Thorac Surg. 1992 Jan;53(1):151-2 [1370196.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1863-8 [1717128.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):119-26 [2423220.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):1994-8 [2458825.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Cancer. 1981 Oct 1;48(7):1647-55 [6169423.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1450-7 [18558665.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1309-15 [18505071.001]
  • [Cites] Surg Oncol. 2007 Dec;16(4):267-75 [17881220.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):857-63 [17320150.001]
  • [Cites] J Dig Dis. 2007 Feb;8(1):23-8 [17261131.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] ANZ J Surg. 2006 Jan-Feb;76(1-2):60-3 [16483298.001]
  • [Cites] Cancer Res. 1972 May;32(5):979-82 [4111729.001]
  • [Cites] N Engl J Med. 1971 Nov 4;285(19):1060-1 [4106199.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1344-50 [4174340.001]
  • [Cites] Cancer Res. 1975 Apr;35(4):991-6 [46783.001]
  • [Cites] Cancer. 1970 Jun;25(6):1261-70 [4987264.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):543-6 [15041508.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1585-95 [15520058.001]
  • (PMID = 19674468.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2731104
  •  go-up   go-down


5. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • Gastric cancer is a major worldwide problem and is a leading cause of death.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


6. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • Patients were excluded if they had previous chemotherapy or radiotherapy treatment, presented early neoplasia, or died during the operations or for other reasons unrelated to cancer.
  • For the survival analysis, cases with distant metastasis upon diagnosis were excluded.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • Both age and apoptosis were independent prognostic factors in cancer of the cardia.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


7. Sohda T, Tomioka Y, Inomata S, Morita I, Eguchi K, Aoyagi K, Watanabe H, Nakamura S, Sakisaka S: Alpha-fetoprotein (AFP)- and des-gamma-carboxy prothrombin (DCP)-producing adenocarcinoma of the stomach with liver metastasis in a patient with chronic hepatitis C. Intern Med; 2005 Apr;44(4):294-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein (AFP)- and des-gamma-carboxy prothrombin (DCP)-producing adenocarcinoma of the stomach with liver metastasis in a patient with chronic hepatitis C.
  • A 45-year-old man was admitted to our hospital because of chronic hepatitis C and a large liver tumor accompanied by increased serum levels of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP), the tumor markers for hepatocellular carcinoma.
  • Endoscopic examination revealed advanced gastric cancer.
  • Biopsy specimens of the stomach and liver showed gastric adenocarcinoma and its metastasis to the liver.
  • Immunohistochemical studies demonstrated that adenocarcinoma cells both of the stomach and liver, were positive for the antibodies against AFP as well as DCP.
  • Expression of AFP mRNA was shown in the cancer cells of the stomach.
  • Accordingly, we diagnosed this patient with AFP- and DCP-producing adenocarcinoma of the stomach together with liver metastasis.
  • [MeSH-major] Adenocarcinoma / secretion. Biomarkers / blood. Hepatitis C, Chronic / complications. Liver Neoplasms / secondary. Protein Precursors / blood. Stomach Neoplasms / secretion. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / blood. Biopsy. Diagnosis, Differential. Fatal Outcome. Follow-Up Studies. Gastroscopy. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prothrombin / genetics. RNA, Messenger / genetics. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Prothrombin.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897638.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / alpha-Fetoproteins; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


8. Jang JS, Yim HJ, Lee BJ, Kim SY, Kim DI, Lee HS, Lee SW, Choi JH: [A case of hepatic metastasis of small cell carcinoma from mixed small cell carcinoma and adenocarcinoma of the stomach]. Korean J Gastroenterol; 2007 Sep;50(3):193-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatic metastasis of small cell carcinoma from mixed small cell carcinoma and adenocarcinoma of the stomach].
  • Primary small cell carcinoma (SCC) of stomach is a rare and highly aggressive malignancy with extremely poor prognosis.
  • We report a 71-year-old man with upper abdominal pain diagnosed as single hepatic metastasis of SCC from mixed SCC and adenocarcinoma of the stomach.
  • An endoscopic examination showed the presence of Borrmann type 2 gastric cancer, 2 cm in size on the lesser curvature of antrum.
  • On the basis of these findings, we made a final diagnosis of mixed SCC and adenocarcinoma of the stomach.
  • Conclusively, we report a case of hepatic metastasis of SCC only from mixed SCC adenocarcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885286.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


9. Mróz A, Kiedrowski M, Malinowska M, Sopyło R: Collision tumour of the stomach--adenocarcinoma and neuroendocrine carcinoma: case report and review of the literature. Pol J Pathol; 2009;60(2):94-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of the stomach--adenocarcinoma and neuroendocrine carcinoma: case report and review of the literature.
  • We report a rare case of gastric collision tumour composed of poorly differentiated adenocarcinoma and neuroendocrine carcinoma in a 56-year-old Caucasian male.
  • The tumour was located in the gastric body and, to our knowledge, it is the tenth case described in the literature and the first in Poland.
  • The adenocarcinoma component constituted 20% of the lesion and was in a more advanced stage than the neuroendocrine component.
  • Additionally, the adenocarcinoma was the only one to metastasize to regional lymph nodes and the liver.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886184.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Szkaradkiewicz A, Majewski W, Wal M, Czyzak M, Majewski P, Bierła J, Kuch A: Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma. Virus Res; 2006 Jun;118(1-2):115-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma.
  • In the presented studies p53 protein expression was evaluated in samples of gastric carcinoma originating from 32 selected adult patients (with documented diagnosis of adenocarcinoma of the stomach and without the presence of Helicobacter pylori infection).
  • Among the patients 14 individuals carried EBV-positive gastric carcinoma (group 1) while the 18 remaining patients carried EBV-negative gastric carcinoma (group 2).
  • Presence of p53 protein was noted in 9 (64.3%) cases of EBV-positive gastric cancer (group 1) and in 10 (55.5%) cases of EBV-negative gastric cancer (group 2).
  • The results permit to conclude that abnormalities in p53 in gastric cancer are independent of EBV infection, even if EBV may participate in development of the tumour.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413625.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Teh SK, Zheng W, Ho KY, Teh M, Yeoh KG, Huang Z: Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach. Br J Surg; 2010 Apr;97(4):550-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach.
  • BACKGROUND: The aim of this study was to evaluate the feasibility of using near-infrared (NIR) Raman spectroscopy for early diagnosis and typing of intestinal and diffuse adenocarcinoma of the stomach.
  • One hundred gastric tissue samples from 62 patients who underwent endoscopy or gastrectomy were used (70 normal tissue specimens and 30 adenocarcinomas).
  • RESULTS: High-quality Raman spectra ranging from 800 to 1800 cm(-1) were acquired from gastric tissue within 5 s.
  • There were significant differences in Raman spectra between normal stomach and the two gastric adenocarcinoma subtypes, particularly in the spectral ranges 850-1150, 1200-1500 and 1600-1750 cm(-1), which contain signals related to proteins, nucleic acids and lipids.
  • PCA-MNLR achieved predictive accuracies of 88, 92 and 94 per cent for normal stomach, and intestinal- and diffuse-type gastric adenocarcinomas respectively.
  • CONCLUSION: NIR Raman spectroscopy can detect gastric malignancy and identify the subtype of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Analysis of Variance. Early Detection of Cancer. Feasibility Studies. Female. Humans. Male. Middle Aged. Spectroscopy, Near-Infrared. Spectrum Analysis, Raman

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20155786.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


12. Martínez-Luna E, Puebla-Miranda M, Vega-Memije ME: [Skin metastasis of gastric adenocarcinoma. Case report]. Rev Gastroenterol Mex; 2009 Oct-Dec;74(4):362-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin metastasis of gastric adenocarcinoma. Case report].
  • [Transliterated title] Metástasis cutáneas de adenocarcinoma gástrico; informe de un caso.
  • These lesions generally occur in late stages of disease, being uncommon their presentation at the time of diagnosis.
  • We inform the case of a male patient who presented a metastatic adenocarcinoma in the skin of the chest.
  • Under the suspect of primary tumor in the gastrointestinal tract, an upper gastrointestinal endoscopy was made corroborating diagnosis of a primary gastric cancer.
  • The case instructs the unusual morphology of cutaneous metastasis of gastric adenocarcinoma, as well appearing as the initial clinical data in an extended malignant disease.
  • Key words: cutaneous metastases, metastatic adenocarcinoma, gastric carcinoma, Mexico.
  • [MeSH-major] Adenocarcinoma / secondary. Skin Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423769.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


13. Muñoz Díaz F, García Carrasco C, Monge Romero MI, de Dios Arrebola García J, Soria Monge A: [Acanthosis nigricans as the initial paraneoplastic manifestation of gastric adenocarcinoma]. Gastroenterol Hepatol; 2007 Jan;30(1):15-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acanthosis nigricans as the initial paraneoplastic manifestation of gastric adenocarcinoma].
  • [Transliterated title] Acantosis nigricans como manifestación inicial paraneoplásica de adenocarcinoma gástrico.
  • Initial treatment with topical corticosteroids and oral antihistamines was unsuccessful and, due to suspicion of a paraneoplastic cutaneous syndrome, gastroscopy with sampling for biopsy and abdominal CT were carried out, revealing the existence of an infiltrating gastric adenocarcinoma and underlying adenopathies.
  • [MeSH-major] Acanthosis Nigricans / etiology. Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes / diagnosis. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266876.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Yang CK, Zhao WJ, Dai QB, Zhang HH, Zheng W: [Clinical characteristics, diagnosis and treatment of hepatoid adenocarcinoma of the stomach]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):245-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics, diagnosis and treatment of hepatoid adenocarcinoma of the stomach].
  • OBJECTIVE: To investigate the clinical characteristics,diagnosis and treatment of hepatoid adenocarcinoma of the stomach.
  • METHODS: Clinical data of 13 hepatoid adenocarcinomas of the stomach, collected from 201 cases of gastric cancer, were analyzed retrospectively.
  • RESULTS: Of the 201 gastric carcinomas, there were 13 AFP-producing adenocarcinomas of the stomach, the positive rate was 6.5%.
  • Of the 13 hepatoid adenocarcinomas of the stomach, 10 cases were in gastric antrum and 10 cases were poorly differentiated.
  • The metastasis rates of liver and lymph node in hepatoid adenocarcinoma of stomach were higher than those in non-hepatoid adenocarcinoma of stomach.
  • The treatment of hepatoid adenocarcinoma of stomach depended mainly on radical resection, and adjuvant chemotherapy was needed.The prognosis of hepatoid adenocarcinoma of stomach was poor.
  • CONCLUSION: Hepatoid adenocarcinoma of the stomach has its own special tumor biological behavior and poor prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520383.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


15. Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M, German Arbeitsgemeinschaft Internistische Onkologie (AIO): Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study.
  • : 4534 Background: Cetuximab has demonstrated high efficacy in combination with irinotecan-based therapies in metastatic colorectal cancer and irinotecan/folinic acid/5-FU (IF) may be an effective alternative to cisplatin-based regimens in advanced gastric cancer.
  • We therefore conducted a phase II AIO study to evaluate the tolerability and efficacy of cetuximab combined with IF as first-line treatment in patients with advanced gastric cancer.
  • METHODS: Patients (pts) were eligible with untreated adenocarcinoma of the stomach or oesophagogastric junction, with ECOG performance status (PS) < 2, measurable lesions and adequate organ functions.
  • RESULTS: Between Aug 2006 and Sep 2007, 49 pts were enrolled: 71% were males, median age was 63 years (range 33-77), median PS was 0 (65% pts), and 69% of pts and 31% of pts had gastric and oesophagogastric junction carcinomas, respectively.
  • Cetuximab combined with chemotherapy in advanced or metastatic gastric cancer is under further investigation in an ongoing phase III trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Single agent GSK089 demonstrates minimal antitumor activity in a cMET-unselected gastric population on the 5 on/9 off schedule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Servarayan CM, Chandramohan A, Datta D, Manickavasagam K: p53 and its influence in adenocarcinoma stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and its influence in adenocarcinoma stomach.
  • : e15685 Background: Gastric cancer is the second most common cause of the malignancy in the world after lung cancer.
  • Various pathogenesis have been given for the adenocarcinoma, like mutation in the E-catherin gene, amplification of COX-2, HGF/ SF, VEGF; deletion of FHIT, APC, p53 but none have provided a definite target for treatment.
  • METHODS: This is a immunohistochemical prospective experiment study done on 76 cases of Gastric Adenocarcinoma.The location of the tumors were recorded as in the proximal stomach (fundus and body) and distal stomach (antrum, prepylorus, and pylorus).
  • 33 out of 60 (55%)of the males and 8 out of 16 (50%) females were reported of having gastric adenocarcinoma with p53expression.
  • The histology of the tissue samples from the gastric adenocarcinoma patients had following relationship with the p53 immunoreactivity, 20 out of 37 cases(54.05%) of the well differentiated,7 out of 17 cases (41.18% )of the moderately differentiated, and and 13 out of 21 cases(61.90%) of the poorly differentiated gastric adenocarcinoma showed positive immunoreactivity.
  • 15 out of 33 cases (45.45%)were localized to the proximal stomach and 30 out of 52 cases (57.69%)were localized to the distal stomach.
  • 52.63 % of the non-mucinous type of gastric adenocarcinoma showed positive p53 immunoreactivity.
  • The mutation is more marked in the poorly differentiated gastric adenocarcinoma.
  • The antral, pylorus,and the prepyloric parts of the stomach( the distal stomach) are more prone for mutated p53 induced adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer.
  • : e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type.
  • The median age of onset for diffuse gastric cancer is 38 years.
  • CDH1 mutations are highly penetrant, conferring a cumulative risk of diffuse gastric cancer of 75%.
  • RESULTS: A pathogenic mutation located on exon 7 of the CDH1 gene was identified in a female patient diagnosed with bilateral breast cancer at the age of 36.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.
  • She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome.
  • The nonsense mutation found was probably maternally inherited, since the maternal grandmother was diagnosed with breast cancer at the age of 38.
  • CONCLUSIONS: The selection process of patients for genetic testing for the HDGC syndrome is not quite clear at the moment, as it is apparent that more types of breast cancer and not only lobular, can be associated with the syndrome.
  • Criteria should be more flexible in respects to the histopathology of the cancer type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Boukovinas I, Androulakis N, Polyzos A, Vardakis N, Amarantidis K, Bozionelou V, Kouroussis C, Giassas S, Christophyllakis C, Mavroudis D: A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer.
  • : 4536 Background: To compare the efficacy and tolerance of two oxaliplatin-based regimens as first-line treatment of advanced gastric cancer.
  • METHODS: Chemotherapy-naïve patients with measurable recurrent or metastatic gastric adenocarcinoma, PS (ECOG) 0-2 and adequate organ functions were randomly assigned to receive either irinotecan 200mg/m2 and oxaliplatin 80mg/m2 (IO), every 21 days or oxaliplatin 85mg/m<sup>2</sup> on day 1, 5-FU 400 mg/m<sup>2</sup> (over 1 hour infusion) + 600mg/m<sup>2</sup> (over 22 hours infusion) on days 1 and 2, leucovorin (LV) 200mg/m<sup>2</sup> on days 1 and 2 (FOLFOX4) every 2 weeks.
  • CONCLUSIONS: Both regimens are well tolerated and active in advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962990.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nakayama N, Koizumi W, Sasaki T, Tanabe S, Nishimura K, Higuchi K, Takagi S, Katada C, Azuma M, Saigenji K: Phase II study of combination therapy with docetaxel, cisplatin, and S-1 (DCS) for advanced gastric cancer: (KDOG 0601). J Clin Oncol; 2009 May 20;27(15_suppl):4555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of combination therapy with docetaxel, cisplatin, and S-1 (DCS) for advanced gastric cancer: (KDOG 0601).
  • : 4555 Background: Our previous phase I study (Oncology 2008, 75:1-7) provided evidence that combination chemotherapy with docetaxel, cisplatin, and S-1 (DCS) is effective and well tolerated in patients with advanced gastric cancer.
  • The present multicenter phase II study was conducted to confirm the efficacy and toxicity of DCS in advanced gastric cancer.
  • METHODS: Eligibility criteria included a histologically proved diagnosis of gastric adenocarcinoma with at least one measurable metastatic lesion, no previous treatment for gastric cancer except for surgery, an ECOG performance status of 0 to 2, and adequate organ function.
  • CONCLUSIONS: DCS was a well-tolerated regimen with a high response rate in patients with advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963030.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Younger people with gastric cancer have poor prognosis. Nurs Stand; 2009 Aug 05;23(48):14-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Younger people with gastric cancer have poor prognosis.
  • : Patients aged 35 and under who present with gastric adenocarcinoma are likely to have a more aggressive tumour type with both locally advanced and metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28038534.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. El-Rayes BF, Patel B, Zalupski M, Hammad N, Shields A, Heilbrun L, Venkatramanamoorthy R, Philip P: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer.
  • : 4563 Background: VEGF (vascular endothelial growth factor) has a central role in angiogenesis, tumor growth and metastasis of gastric cancer.
  • METHODS: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction treated with docetaxel, oxaliplatin and bevacizumab.
  • RESULTS: A total of 23 patients (median age 57, males 70%, gastric 52%) were enrolled on the study.
  • At this time, bevacizumab should not be used in gastric or gastroesophageal junction cancers outside of a clinical trial until its safety is well established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL: Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.
  • We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
  • METHODS: Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers.
  • Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
  • RESULTS: 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lu M, Shen L: Recurrence patterns of Chinese patients with gastric cancer after complete resection. J Clin Oncol; 2009 May 20;27(15_suppl):e15667

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns of Chinese patients with gastric cancer after complete resection.
  • : e15667 Background: Recurrence after radical resection was the most important factor that influence the prognosis of patients with gastric adenocarcinoma.
  • Focusing on the clinicopathologic features and recurrence patterns, this study aims to find the characteristics of recurrence pattern and the predictive factors of gastric cancer patients in China.
  • METHODS: This is a retrospective analysis of the gastric adenocarcinoma patients who accepted adjuvant treatment and follow up in our medical department after R0 resection.
  • Locoregional recurrence was defined as dominant masses in the gastric bed, regional nodes or anastomotic recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Mohri Y, Kageyama S, Mohri T, Tanaka K, Ohi M, Yokoe T, Kusunoki M: Macrophage migration inhibitory factor and long-term survival in gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor and long-term survival in gastric cancer.
  • : e15525 Background: Our study aimed to evaluate whether pretherapeutic serum macrophage migration inhibitory factor (MIF) is an independent factor predicting long-term survival in gastric cancer.
  • Gastric cancer is the second leading cause of cancer-related deaths worldwide, but no satisfactory tumor marker exists.
  • We recently found serum MIF expression was progressively increased in gastric cancer.
  • METHODS: One hundred five patients, 73 men and 32 women, mean (±SD) age 63±14 years, with histologically proven gastric adenocarcinoma were included in the study.
  • CONCLUSIONS: The serum level of MIF is a potentially valuable pretherapeutic prognostic factor in patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962256.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kakeji Y, Mizokami K, Sumiyoshi Y, Yoshinaga K, Saeki H, Tokunaga E, Endo K, Morita M, Kitao H, Emi Y, Maehara Y: The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma.
  • The clinicopathological characteristics of human gastric cancer and the clinical outcomes were analyzed to investigate the effects of the expression of hypoxia-inducible factor1α (HIF-1α) and some related proteins, such as, vascular endothelial growth factor (VEGF), insulin-like growth factor-2 (IGF-2), p21, and p53 on the prognosis of human gastric cancer.
  • METHODS: The expressions of HIF-1α, VEGF, IGF-2, p21, and p53 proteins were determined by immunohistochemistry in 216 specimens of primary gastric cancer.
  • In addition, the HIF-1α expression positively correlated with the tumor size and depth of invasion, while it was also more frequent in tumors with lymphatic invasion and undifferentiated adenocarcinomas.
  • A multivariate Cox regression analysis showed the depth of invasion, lymph node metastasis, and HIF-1α positivity to all be independent prognostic factors in patients with gastric cancer.
  • CONCLUSIONS: Based on the above findings, HIF-1α is therefore considered to be a useful independent prognostic factor in gastric cancer, and the combination of a HIF-1α protein overexpression with the loss of p21 expression or nonfunctional p53 thus tends to indicate a dismal prognosis.
  • Controlling hypoxia, especially in the HIF-1α pathways, may therefore hold the key to a greater individualization of therapy and also lead to the development of new treatments for patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lin R, Chen Q, Fan N, Ye Y, Guo Z, Wang X, Liu J, Chen L: Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC).
  • METHODS: Patients with previously untreated, advanced, unresectable, and histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction were randomly assigned to POF or IF regiment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Cho S, Lee S, Hwang J, Bae W, Shim H, Park C, Park M, Chung I: Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer.
  • In previous study, S-1 demonstrated promising activity which is comparable to combination chemotherapy in advanced gastric cancer.
  • This phase II study evaluated the efficacy and safety of S-1 salvage chemotherapy, in patients with taxane and cisplatin refractory gastric cancer.
  • METHODS: Patients were eligible if they had histologically documented gastric adenocarcinoma previously treated with taxane (docetaxel or paclitaxel) and cisplatin; age≥18; Eastern Clinical Oncology Group (ECOG) performance status of 2 or less; adequate organ function; no evidence of gastrointestinal obstruction or passage disturbance.
  • CONCLUSIONS: This results showed that S-1 monotherapy was active and safe salvage chemotherapy in patients with advanced gastric cancer previously treated with taxane and cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963034.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, Schumacher G, Gebauer B, Maier V, Reichardt P: Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):4540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • : 4540 Background: Up to now the value of 2<sup>nd</sup>-line therapy for metastatic gastric cancer is unclear.
  • In this randomized phase III study we compared irinotecan to BSC to evaluate the value of 2<sup>nd</sup>- line chemotherapy for gastric cancer.
  • Eligibility: Metastatic or locally advanced gastro-esophageal junction or gastric adenocarcinoma.
  • CONCLUSIONS: To our knowledge this is the first randomized phase III study investigating 2<sup>nd</sup>- line chemotherapy in gastric cancer.
  • 2<sup>nd</sup>-line chemotherapy can now be considered as a proven option in gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol; 2009 May 20;27(15_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).
  • : 4545 Background: Gastric cancer (GC) with peritoneal metastasis (PM) often complicates ascites or intestinal stenosis and the prognosis is still poor.
  • Anti-cancer drugs generally can not be administered for such patients (pts) due to the risk of serious and prolonged adverse events.
  • METHODS: Eligibility criteria included pts with histologically proven gastric adenocarcinoma; inoperable or recurrent GC; PM with radiologically confirmed intestinal stenosis or ascites; 20-75 years old; PS 0-2; no prior treatment except surgery or adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.
  • : e15599 Background: The role of the second line chemotherapy in advanced gastric cancer was not clear, but possibility of prolongation of survival is open question.
  • Irinotecan is promising agents in gastric cancer and this phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, high dose of 5-fluorouracil (5-FU) and leucovorin in taxane and cisplatin based chemotherapy refractory metastatic gastric cancer.
  • METHODS: Eligible criteria were as followed; histologic confirmed adenocarcinoma of stomach, previously treated with taxane and cisplatin, age≥18, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, adequate organ function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Lee J, Kang W, Lim D, Park J, Park Y, Lim H, Sohn T, Noh J, Bae J, Kim S: Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.
  • : 4537 Background: Although the adjuvant chemoradiation therapy has gained popularity and has become the standard of care in patients with resected gastric cancer in U.S., the role of chemoradiation therapy after extended D2 dissection has been questioned.
  • We conducted a phase III trial to compare capecitabine/cisplatin (XP) vs XP + radiotherapy (RT) in curatively D2 resected gastric cancer patients in terms of disease free survival and overall survival.
  • METHODS: Eligibility criteria were as follows: stage Ib (T1N1, T2bN0) - IV (M1 excluded), curatively ≥ D2 resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962988.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gallego R, Fuster D, Ginés A, Ortín J, Ayuso JR, Momblan D, Arguis P, Conill C, Pons F, Maurel J: Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma.
  • 1) To evaluate the usefulness of Positron Emission Tomography with combined 18F-Fluorodeoxyglucose with Computed Tomography (PET/CT) in the diagnosis of distant metastases in patients with gastric adenocarcinoma (GAC) compared to spiral double contrast thoracoabdominal Computed Tomography (CT);.
  • METHODS: Thirty prospective patients (22 men, 8 women; mean age 67±11) who underwent endoscopic ultrasound and were classified as T2-3N1 or T3Nx GAC were included in this study.
  • In 1/3 patients with histopathological confirmed diagnosis of peritoneal carcinomatosis by laparoscopic findings was negative by PET/CT, and considered as a false negative case.
  • 1) PET/CT is useful in the diagnosis of distant metastases in patients with GAC 2) Further studies are needed to establish the role of PET/CT to detect peritoneal carcinomatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962880.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kim S, Kim J, Chae Y, Sohn S, Moon J, Kang B, Chung H, Yu W, Baek J: Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer.
  • : e15638 Background: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NKFB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma.
  • METHODS: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study.
  • The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer.
  • CONCLUSIONS: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Woell E, Greil R, Eisterer W, Fridrik M, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Thaler J: Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). J Clin Oncol; 2009 May 20;27(15_suppl):4538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT).
  • : 4538 Background: Patients (pts.) suffering from advanced gastric cancer have still a poor prognosis and treatment options are limited.
  • In our previous phase II trial (AGMT-Gastric-1) we could show that the combination of oxaliplatin and irinotecan was well tolerated and showed an objective response rate of 58% (Anticancer Res 28:2901-2906, 2008).
  • 51 patients with histological proven unresectable and/or metastatic gastric adenocarcinoma were treated in a first line setting.
  • CONCLUSIONS: The combination of oxaliplatin and irinotecan with cetuximab is feasible, safe and active in advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • : e15658 Background: Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • METHODS: We analyzed 54 cases of cytological confirmed gastric LMC at 4 institutions from 1994 to 2007.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • The median interval from the diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 months (range, 0 - 73.1 months).
  • Median OS duration from diagnosis of LMC was 6.7 weeks (95% CI; 4.3-9.1 weeks).
  • CONCLUSIONS: Although gastric LMC has dismal prognosis, IT and IV chemotherapy could be help to extend survival duration of gastric LMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Glehen O, Elias D, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Association Française de Chirurgie: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50).
  • The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol; 2009 May 20;27(15_suppl):4510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
  • : 4510 Background: Combined pre- and postoperative chemotherapy improves overall survival in operable gastric cancer, although postoperative treatment is not feasible in half of the patients.
  • METHODS: Patients with locally advanced adenocarcinoma of the stomach and cardia were randomized between primary surgery or two 48-day cycles of weekly folinic acid 500 mg/m<sup>2</sup>/2h, 5-FU 2,000 mg/m<sup>2</sup>/24h plus biweekly cisplatin 50 mg/m<sup>2</sup>/1h followed by surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Sym S, Park S, Park J, Kwon K, Jung I, Cho E, Lee W, Chung M, Shin D, Lee J: A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results.
  • METHODS: Chemotherapy-naïve patients with measurable unresectable and/or metastatic gastric adenocarcinoma and a performance status ≤2 were randomly assigned to receive docetaxel (35 mg/m2) weekly on days 1 and 8 of a 21-day cycle plus either cisplatin (60 mg/m2 on day 1) (arm A) or oxaliplatin (120 mg/m2 on day 1) (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Moon Y, Rha S, Jeung H, Shin S, Yoo N, Roh J, Noh S, Chung H: Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer.
  • : e15521 Background: Little is known about data on subsequent chemotherapy (CTx) following 1<sup>st</sup>-line CTx in stage IV gastric cancer.
  • The purpose of this study was to analyze the natural history of stage IV gastric cancer with sequential CTx Methods: A total of 532 patients (pts) with unresectable gastric adenocarcinoma were studied.
  • Median overall survivals from diagnosis of unresectable cancer were 12.0/13.3/2.5 months for overall/CTx/BSC, respectively.
  • CONCLUSIONS: When pts with unresectable gastric cancer were managed with a strategy of maximal administration of CTx, a considerable number of pts could receive 2<sup>nd</sup> or 3<sup>rd</sup> line CTx, showing modest activity.
  • Our data on the natural history of stage IV gastric cancer with sequential CTx may suggest that clinical trials can be performed in a 2<sup>nd</sup> or 3<sup>rd</sup> line setting as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Aziz SA, Banday MA, Mir MH: Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach.
  • : e15639 Background: Outcome of carcinoma of stomach has not changed over the past decades and surgery remains the time tested primary modality of treatment.
  • The present study focuses to compare the efficacy of adjuvant chemoradiation Vs Chemotherapy alone in surgically resected adenocarcinoma of stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Shibahara H, Arai T, Yokoi S, Hayakawa S: Bronchogenic cyst of the stomach involved with gastric adenocarcinoma. Clin J Gastroenterol; 2009 Apr;2(2):80-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchogenic cyst of the stomach involved with gastric adenocarcinoma.
  • Bronchogenic cyst, a congenital anomaly mostly found in the mediastinum, rarely arises in the stomach.
  • A 43-year-old man had epigastric pain and was diagnosed as having gastric adenocarcinoma.
  • Abdominal ultrasonography showed hepatic cyst, and computed tomography and magnetic resonance imaging revealed a cystic lesion near the stomach.
  • At surgery, the cystic lesion was found to be located at the lesser curvature of the stomach where the cancer invasion was seen.
  • The pathological diagnosis was bronchogenic cyst of the stomach involved with gastric adenocarcinoma.
  • Based on a similar association between gastric diffuse submucosal cysts and gastric cancer in the previous reports, it is possible that chronic inflammation from bronchogenic cysts to the gastric mucosa may cause adenocarcinoma in the stomach.
  • At surgery, complete combined resection without rupture of the bronchogenic cyst involved with the gastric adenocarcinoma is needed for treatment of gastric cancer to prevent dissemination of cancer cells considering when cancer cells have invaded beyond the pseudostratified ciliated columnar epithelium and within the bronchogenic cyst.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26192170.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Adenocarcinoma / Bronchogenic cyst / Stomach
  •  go-up   go-down


43. Baba H, Fujiwara N, Nakamura H, Tanaka K, Kuwabara H, Tamai S, Nakajima K, Goseki N, Shimoda S: [Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2051-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach].
  • Gastrointestinal endoscopy revealed a giant ulcer at distal portion of the stomach.
  • Final pathology report was undifferentiated adenocarcinoma of the stomach, exposing itself to serosa with lymph node metastasis.
  • Undifferentiated adenocarcinoma of the stomach is rare disease.
  • Immunohistochemical staining is useful for a differential diagnosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106520.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


44. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in young adults; comparative study with older patients].
  • [Transliterated title] Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.
  • BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age.
  • The aim of thisΩ demographic, clinicopathological and prognosis of gastric cancer in young patients and to compare their features with the behavior in elder adults.
  • CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor.
  • For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


45. Sánchez-Fayos P, Martín Relloso MJ, González Guirado A, Porres Cubero JC: [Gastric adenocarcinoma: approach to a complex biological reality]. Med Clin (Barc); 2007 Jan 13;128(1):21-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma: approach to a complex biological reality].
  • [Transliterated title] Adenocarcinoma gástrico: intento de aproximación a una realidad biológica compleja.
  • The authors review the complex biological reality of gastric adenocarcinoma from several viewpoints.
  • A good knowledge of this complex biological reality will allow the identification of better markers for an early diagnosis as well as vulnerable etiopathogenetic points for a useful prevention and therapy.
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms
  • [MeSH-minor] Achlorhydria / complications. Aged. Diet / adverse effects. Early Diagnosis. Epithelial Cells / cytology. Epithelial Cells / pathology. Female. Gastric Mucosa / pathology. Gastritis, Atrophic / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Male. Metaplasia. Middle Aged. Mitosis. Precancerous Conditions / chemically induced. Precancerous Conditions / pathology. Risk Factors. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266889.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 107
  •  go-up   go-down


46. Augustin G, Jelincic Z, Tentor D, Majerovic M, Matosevic P: Hepatoid adenocarcinoma of the stomach: case report and short notes on immunohistochemical markers. Acta Gastroenterol Belg; 2009 Apr-Jun;72(2):253-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach: case report and short notes on immunohistochemical markers.
  • Hepatoid adenocarcinoma of the stomach is a rare type of gastric carcinoma with an extremely poor prognosis.
  • We describe a 72-year-old man who underwent esophagogastroduodenoscopy which revealed 50 mm exulcerated lesion with a central necrosis on the lesser curvature and the posterior wall of the body of the stomach.
  • Gastric biopsy revealed a poorly differentiated (anaplastic) adenocarcinoma.
  • After diagnosis of AFP-producing gastric adenocarcinoma, total gastrectomy, with splenectomy, was performed.
  • According to these histopathological and immunohistochemical findings, the tumor was diagnosed as hepatoid adenocarcinoma.
  • Because of the poor prognosis for this histological type of tumor, accurate diagnosis of hepatoid adenocarcinoma is important, and long-term follow-up is required.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637784.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


47. Muroni M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, Pilozzi E, Ramacciato G: Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):97-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
  • BACKGROUND: The association between gastric and pancreatic carcinoma is a relatively rare condition.
  • In gastric carcinoma patients, the prevalence of second tumors varies 2.8% to 6.8% according to the reported statistics.
  • Gastric cancer associated with pancreatic cancer is uncommon.
  • Esophagogastroduodenoscopy demonstrated an ulcerative lesion of the gastric antrum.
  • Computed tomography and magnetic resonance showed a gastric thickening in the antral and pyloric portion and a nodular mass (3 X 1.7 cm) in the uncinate portion of the pancreas.
  • Histological examination of the specimen demonstrated a moderately differentiated adenocarcinoma of the stomach and a poorly differentiated ductal adenocarcinoma of the pancreas.
  • CONCLUSIONS: Long survival is rare in patients with associated gastric and pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133238.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Chekrine T, Tawfiq N, Bouchbika Z, Benchakroun N, Jouhadi H, Sahraoui S, Benider A: [Ocular metastasis heralding gastric adenocarcinoma]. Rev Med Interne; 2010 Oct;31(10):e14-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular metastasis heralding gastric adenocarcinoma].
  • [Transliterated title] Métastase oculaire inaugurale d'un adénocarcinome gastrique.
  • Ocular metastasis is a rare presenting feature of gastric adenocarcinoma.
  • Diagnostic work-up identified a gastric adenocarcinoma with pulmonary metastases.
  • The patient died 6 months after the diagnosis of respiratory failure.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20554090.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


49. Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, Tsujii S, Onishi S, Kobayashi M, Hanazaki K: Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg; 2008 Feb;206(2):306-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach?
  • BACKGROUND: Although the incidence of gastric cardia cancer is considerably less than more distal gastric cancer, the rate of occurrence is now increasing.
  • The objective of this study was to evaluate and compare the clinicopathologic findings of gastric cardia and more distal stomach adenocarcinoma.
  • STUDY DESIGN: Patients included in our study were those who underwent operations for gastric adenocarcinoma in our institute from 1981 to 2006, and who had undergone complete medical history, including history of daily alcohol consumption; smoking; body mass index; and pathologic examinations.
  • A total of 843 patients were included in our study, and were divided into cardia and noncardia cancer groups.
  • RESULTS: Among the 843 patients, 23 (2.8%) had gastric cardia cancer.
  • Although noncardia cancer was often detected at an early stage, gastric cardia cancer was most often diagnosed at an advanced stage.
  • Pathologically, cardia cancer was more invasive and had more lymphatic permeation and lymph node metastasis than noncardia cancer.
  • CONCLUSIONS: Gastric cardia cancer occurs at a low incidence of only 2.8% of resected gastric cancers.
  • Unlike cases of gastric cardia cancer in Western populations, body mass index is not associated with occurrence of gastric cardia cancer in our study.
  • Because gastric cardia cancer appears more aggressive than noncardia gastric cancer, early diagnosis and intervention are important.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222384.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Jalle T, Gérard C, Lada PE, Sagan C, Gournay J, Arnaud JP, Paineau J, Hamy A: [Hepatoid adenocarcinoma of the stomach. A case report]. Ann Chir; 2006 Mar;131(3):213-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatoid adenocarcinoma of the stomach. A case report].
  • [Transliterated title] Adénocarcinome hépatoïde de l'estomac. A propos d'un cas.
  • Hepatoid adenocarcinoma of the stomach is a very rare tumor with a poor prognosis.
  • Diagnosis should be pointed out if elevated serum level of alpha-fetoprotein (AFP) is detected with gastric tumor.
  • Histologically, the tumor is an adenocarcinoma of intestinal type including foci of hepatoïd differenciation.
  • We report a case of a 66 year-old man presenting an advanced stage of hepatoid adenocarcinoma of the stomach, treated by gastrectomy followed by chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293220.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


51. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Intestinal adenocarcinomas were analysed immunohistochemically for the presence of ER alpha, beta and beta cx.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cohort Studies. Disease Progression. Female. Gastric Mucosa / metabolism. Humans. Middle Aged. Receptors, Estrogen / metabolism. Risk Factors. Stomach / metabolism. Sweden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


52. Kaira K, Sunaga N, Yanagitani N, Hisada T, Ishizuka T, Mori M: Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer. Australas Radiol; 2007 Dec;51 Suppl:B265-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer.
  • Pseudomesotheliomatous adenocarcinoma is an uncommon variant of peripheral lung cancer.
  • An immunohistochemical investigation is important when it is difficult to determine whether diffuse carcinomatous involvement of the pleura is secondary to metastasis, lung cancer, or mesothelioma.
  • We herein report a very rare case of concomitant pseudomesotheliomatous adenocarcinoma, gastric cancer and esophageal cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Imaging / methods. Esophageal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Neoplasms, Second Primary / diagnosis. Stomach Neoplasms / diagnosis


53. Saad N, Hot A, Ninet J, Claudy A, Faure M: [Acquired hypertrichosis lanuginosa and gastric adenocarcinoma]. Ann Dermatol Venereol; 2007 Jan;134(1):55-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired hypertrichosis lanuginosa and gastric adenocarcinoma].
  • [Transliterated title] Hypertrichose lanugineuse acquise et adénocarcinome gastrique.
  • We report a case in which this hypertrichosis allowed diagnosis of gastric cancer.
  • Clinical examination led to diagnosis of acquired hypertrichosis lanuginosa, which subsequently resulted in the discovery of gastric adenocarcinoma.
  • Our finding is original since it is the first recorded case of association with gastric adenocarcinoma.
  • Two hypotheses have nevertheless been suggested: acquired hypertrichosis lanuginosa could be associated with secretion by the tumour of an as yet unidentified serum factor, or with a nutritional deficiency that may accompany this form of cancer.
  • [MeSH-major] Adenocarcinoma / complications. Hypertrichosis / etiology. Paraneoplastic Syndromes / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Hypertrichosis lanuginosa, acquired.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384545.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Biffoni M, Macrina N, Napoli A, Amabile MI, Cavallo Marincola B, Anzidei M, Catalano C, Maturo A, Pasta V: [Mucinous gastric adenocarcinoma and duodenal somato-statinoma. Case report]. G Chir; 2008 Aug-Sep;29(8-9):339-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous gastric adenocarcinoma and duodenal somato-statinoma. Case report].
  • [Transliterated title] Adenocarcinoma gastrico di tipo mucinoso associato a somatostatinoma duodenale. Case report.
  • The Authors present a rare association of gastric adenocarcinoma and somatostatin-producing duodenal carcinoid.
  • The pre-operative abdominal CT scan revealed the gastric lesions and a duodenal polypoid lesion, giving an important indication to perform a subtotal gastrectomy and a duodenal resection.
  • The definitive diagnosis was possible with histological examination.
  • [MeSH-major] Adenocarcinoma. Duodenal Neoplasms. Neoplasms, Multiple Primary. Somatostatinoma. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18834564.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


55. Sarela AI, Yelluri S, Leeds Upper Gastrointestinal Cancer Multidisciplinary Team: Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary? Arch Surg; 2007 Feb;142(2):143-9; discussion 149
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma with distant metastasis: is gastrectomy necessary?
  • HYPOTHESIS: For distant metastatic (M1) gastric adenocarcinoma, a policy to maximally avoid resection of the primary tumor is safe and efficacious.
  • PATIENTS: Sixty-seven (32%) of 211 consecutive patients with adenocarcinoma of the stomach or gastroesophageal junction had synchronous M1 disease on computed tomography or laparoscopy.
  • RESULTS: Fourteen patients (25%) had intervention a median of 5 months after diagnosis.
  • Intervention was for gastric obstruction (20%), bleeding (7%), or perforation (2%).
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309965.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


56. Comez G, Pehlivan Y, Kalender ME, Sevinc A, Sari I, Camci C: Synchronous Hodgkin's disease and gastric adenocarcinoma. Oncology; 2007;73(5-6):422-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous Hodgkin's disease and gastric adenocarcinoma.
  • BACKGROUND: Adenocarcinoma is the most frequent pathological type of stomach cancer.
  • CASE: Here we present a 52-year-old male complaining of epigastric pain and fever diagnosed as stomach adenocarcinoma and Hodgkin's lymphoma.
  • CONCLUSION: It is thought that this case is the first of a synchronous stomach adenocarcinoma and Hodgkin's lymphoma encountered in the English literature.
  • It should be kept in mind that second malignancies can be seen in mass lesions in patients diagnosed with cancer.
  • [MeSH-major] Adenocarcinoma / complications. Hodgkin Disease / complications. Stomach Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / radiography. Reed-Sternberg Cells / pathology. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18523360.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


57. Lu CC, De-Chuan C, Lee HS, Chu HC: Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases. Am J Surg; 2010 Apr;199(4):e42-4
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure hepatoid adenocarcinoma of the stomach with spleen and lymph-node metastases.
  • The authors report a rare case of hepatoid adenocarcinoma of the stomach, presenting initially with spleen and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cardia. Liver Neoplasms / diagnosis. Lymph Nodes / pathology. Splenic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20359564.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins; 8001-40-9 / Iodized Oil; 80168379AG / Doxorubicin
  •  go-up   go-down


58. Yamamoto J, Ohshima K, Kohno S, Ichimiya H, Nakagaki M, Yao T, Iwasaki H, Ikeda S: Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case. Surg Today; 2005;35(6):488-92
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well differentiated adenocarcinoma of the stomach diagnosed preoperatively as esophageal achalasia: report of a case.
  • Extremely well differentiated primary gastric adenocarcinoma, which accounts for less than 0.2% of all gastric cancers, is associated with a better prognosis than other types of differentiated adenocarcinoma.
  • Among 2070 gastric carcinomas, diagnosed between 1983 and 2002 at Fukuoka University Hospital and Hamanomachi Hospital, there were three cases of primary extremely well differentiated adenocarcinoma.
  • We report the clinicopathological details of one case of primary gastric extremely well differentiated adenocarcinoma.
  • A 57-year-old man was reffered to our hospital for investigation and treatment of a gastric tumor.
  • Macroscopically, the surgical specimen contained a submucosal tumor, and histological examination revealed extremely well differentiated adenocarcinoma.
  • Although this type of carcinoma is very rare, it should be considered in the differential diagnosis of esophageal and gastric mucosal lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Achalasia / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Cardia / pathology. Cell Differentiation. Cholecystectomy. Endoscopy, Digestive System. Esophagus / radiography. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • Genetic Alliance. consumer health - Achalasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912298.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. Lu HZ, Wu YP, Luo W, Han YL, Cai Y, Xu X, Liang J, Liu SM, Wang MR: [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):754-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma].
  • OBJECTIVE: The purpose of this study was to investigate the markers which can be used in auxiliary diagnosis of gastric adenocarcinoma (GAC), and their correlation with their clinicopathological features.
  • METHODS: 122 surgical specimens including 99 gastric adenocarcinoma (GAC), 18 adjacent mucosa and 5 distal normal mucosa were collected, and analyzed by in situ hybridization (FISH).
  • The centromere probe cen17, specific for chromosome 17, which was reported to be frequently amplified in GAC, was selected for the FISH analysis.
  • The clinicopathological features of the 99 GAC cases were reviewed, and the level of TP53 and TOPIIalpha gene expression, located in chromosome 17, was detected using tissue micro-array (TMA), compared with that of corresponding adjacent normal mucosa.
  • RESULTS: The statistical results of FISH and TMA showed that 58.6% of cen17 in tumor tissues were aneuploid, and 45.5% of TP53 and 84.7% of TOPIIalpha were over-expressed in GAC samples, significantly higher than those in non-tumor gastric mucosa (0, 12.1% and 14.1%, respectively) (P = 0.000).
  • 58 GAC tissues were aneuploid of cen17, including 26 cases TP53-positive and 49 cases TOPIIalpha-positive.
  • The expression of TP53 in non-tumor gastric mucosa with dysplasia was significantly higher than that in the mucosa without dysplasia (P = 0.009).
  • Aneuploidy of cen17 was more frequent in grade 1 or 2 than in grade 3 GAC (P < 0.05).
  • Higher frequency of aneuploidy of cen17 was also observed in the gastric cardia than in pylorus (P < 0.05), while no correlation was found between aneuploidy of cen17 and age, sex of patients, lymph node metastasis, and clinical stage of tumors.
  • CONCLUSION: Detection of aneuploidy of cen17 as well as over-expression of TP53 and TOPIIalpha may be helpful in the diagnosis and prognostic prediction of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aneuploidy. Antigens, Neoplasm / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Stomach Neoplasms. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


60. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol; 2007 Oct;18(10):1673-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
  • BACKGROUND: Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but high rates of hematologic toxicity in advanced gastric cancer.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with advanced gastric-/esophageal adenocarcinomas received T 50 mg/m(2) and P 50 mg/m(2) on days 1, 15 and 29 and L 500 mg/m(2) plus F 2000 mg/m(2) weekly, every 8 weeks.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660494.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Kanechorn Na Ayuthaya R, Patthamapasphong N, Sura T, Niumpradit N, Trachoo O: Ehlers-Danlos syndrome type IV with gastric adenocarcinoma. J Med Assoc Thai; 2008;91 Suppl 1:S166-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ehlers-Danlos syndrome type IV with gastric adenocarcinoma.
  • OBJECTIVES: To encourage a better understanding of vascular EDS as a basis for early diagnosis, prevention, and management of complications.
  • A first case of EDS type IV with adeno-carcinoma of the stomach in Thailand was reported and literature was reviewed.
  • Abdominal aortic aneurysm were detected with upper gastrointestinal hemorrhage, esophagogastroduodenoscopy showed diffuse gastric body swelling and erythema resulting in chronic gastritis.
  • Gastric biopsy was indicative of adenocarcinoma of the stomach and gastrectomy was done.
  • [MeSH-major] Adenocarcinoma / complications. Ehlers-Danlos Syndrome / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Ehlers-Danlos syndrome.
  • MedlinePlus Health Information. consumer health - Ehlers-Danlos Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672610.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / COL3A1 protein, human; 0 / Collagen Type III
  •  go-up   go-down


62. Karim S, Ali A: Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol; 2009 Mar 21;15(11):1381-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India.
  • AIM: To study the alterations in p53 gene among Indian gastric cancer patients and to correlate them with the various clinicopathological parameters.
  • METHODS: A total of 103 gastric cancer patients were included in this study.
  • [MeSH-major] Adenocarcinoma / genetics. Exons / genetics. Gene Expression Regulation, Neoplastic. Genes, p53. Mutation. Polymerase Chain Reaction / methods. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Gastric Mucosa / physiology. Gastric Mucosa / physiopathology. Gene Amplification. Humans. Immunohistochemistry. India. Polymorphism, Single-Stranded Conformational. Reference Values. Stomach / physiology. Stomach / physiopathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1999 Oct;50(4):594-5; discussion 595-6 [10502192.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Am Surg. 2007 Apr;73(4):359-66 [17439029.001]
  • [Cites] J Gastroenterol. 2000;35 Suppl 12:111-5 [10779229.001]
  • [Cites] Indian J Gastroenterol. 2000 Apr-Jun;19(2):74-8 [10812820.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:121-37; discussion 137-9 [10911910.001]
  • [Cites] East Afr Med J. 2000 Jan;77(1):27-30 [10944835.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):207-16 [11315254.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):727-31 [12115507.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):585-90 [15166261.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2174-8 [15259060.001]
  • [Cites] Pathobiology. 2004;71(4):201-10 [15263809.001]
  • [Cites] Cell. 1982 Feb;28(2):387-94 [6277513.001]
  • [Cites] Science. 1987 Oct 9;238(4824):193-7 [2889267.001]
  • [Cites] Genomics. 1989 Nov;5(4):874-9 [2687159.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 [1933891.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Jan;4(1):1-15 [1377002.001]
  • [Cites] J Pathol. 1992 Apr;166(4):329-30 [1517889.001]
  • [Cites] PCR Methods Appl. 1991 Aug;1(1):34-8 [1842918.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):265-72 [8440743.001]
  • [Cites] Gut. 1993 Mar;34(3):289-92 [8472973.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2614-7 [8495424.001]
  • [Cites] Genomics. 1993 May;16(2):325-32 [8314571.001]
  • [Cites] Am J Obstet Gynecol. 1993 Sep;169(3):690-4 [8372881.001]
  • [Cites] Hum Mutat. 1993;2(5):338-46 [8257985.001]
  • [Cites] J Pathol. 1993 Oct;171(2):151-2 [8283352.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 1;75(1):45-50 [8039163.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1251-5 [8067692.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):585-90 [7917901.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2391-411 [7919359.001]
  • [Cites] J Pathol. 1994 Jan;172(1):1-4 [7931821.001]
  • [Cites] J Pathol. 1994 Jan;172(1):5-12 [7931827.001]
  • [Cites] Oncogene. 1995 Feb 16;10(4):681-8 [7862445.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):707-13 [7571667.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1244-9 [8608498.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):307-15 [8658214.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Nov;11(11):1083-8 [8985835.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):189-94 [9261746.001]
  • [Cites] Dig Dis Sci. 1997 Dec;42(12):2463-7 [9440620.001]
  • (PMID = 19294769.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2658834
  •  go-up   go-down


63. Bazuro GE, Torino F, Gasparini G, Capurso L: Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? Minerva Gastroenterol Dietol; 2008 Dec;54(4):429-44
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
  • Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed.
  • Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio.
  • The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions.
  • The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies.
  • The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance.
  • In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.
  • [MeSH-major] Adenocarcinoma / prevention & control. Gastrointestinal Neoplasms / prevention & control
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Esophageal Neoplasms / prevention & control. Humans. Mesalamine / therapeutic use. Probiotics / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Stomach Neoplasms / prevention & control

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047983.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 4Q81I59GXC / Mesalamine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; R16CO5Y76E / Aspirin
  • [Number-of-references] 102
  •  go-up   go-down


64. Vlachostergios PJ, Voutsadakis IA, Barbanis S, Karasavvidou F, Papandreou CN: AFP-producing hepatoid adenocarcinoma of the stomach: a case report. Cases J; 2009;2:9296
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AFP-producing hepatoid adenocarcinoma of the stomach: a case report.
  • Hepatoid gastric adenocarcinoma is a distinct variant of gastric carcinoma which represents a comparatively small percentage of the disease and in many cases is producing high serum alpha-fetoprotein (AFP).
  • We report a case of an 85 year old woman who presented with epigastric and right upper quadrant pain and was found in a CT scan to have multiple liver nodules and a gastric antrum mass as well as an elevated AFP level of 155000 IU/ml.
  • An endoscopic biopsy of the antral mass showed hepatoid variant of gastric adenocarcinoma.
  • The patient refused any further treatment and died 4 months after diagnosis.
  • Hepatoid gastric adenocarcinoma is considered to have a poor prognosis, although cases with survival of several years have been reported.
  • Poor outcome in most of the cases is due to the fact that, as in our patient, metastatic disease is already present at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] J Comput Assist Tomogr. 2007 Nov-Dec;31(6):846-52 [18043368.001]
  • [Cites] Histopathology. 1995 Feb;26(2):171-5 [7537718.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):687-91 [11462904.001]
  • [Cites] Kurume Med J. 2003;50(1-2):63-6 [12971266.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1241-4 [14560160.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Jan;28(1):77-9 [15041816.001]
  • [Cites] Pathology. 2005 Jun;37(3):211-5 [16175893.001]
  • [Cites] Hepatogastroenterology. 2005 Nov-Dec;52(66):1930-2 [16334809.001]
  • [Cites] Abdom Imaging. 2007 May-Jun;32(3):293-8 [16967243.001]
  • [Cites] J Dig Dis. 2007 Feb;8(1):23-8 [17261131.001]
  • [Cites] Surg Today. 2007;37(11):995-9 [17952534.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):464-75 [18204429.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1302-12 [14508391.001]
  • [Cites] Ann Diagn Pathol. 2004 Jun;8(3):137-41 [15185260.001]
  • [Cites] Ann Chir. 2006 Mar;131(3):213-5 [16293220.001]
  • [Cites] Histopathology. 2006 Nov;49(5):479-86 [17064293.001]
  • [Cites] World J Surg Oncol. 2007;5:79 [17634124.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):119-26 [2423220.001]
  • (PMID = 20062620.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803960
  •  go-up   go-down


65. Gazvoda B, Juvan R, Zupanic-Pajnic I, Repse S, Ferlan-Marolt K, Balazic J, Komel R: Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA. Eur J Gastroenterol Hepatol; 2007 Dec;19(12):1082-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA.
  • OBJECTIVES: Adenocarcinoma of the stomach is a relatively frequent malignant disease in Slovenia.
  • We investigated the frequency of microsatellite instability (MSI) and loss of heterozygosity (LOH) in gastric carcinomas from the Slovenian population to determine their prognostic significance.
  • LOH-N status was associated with diagnosis at higher TNM status (0.074) and infiltrative growth (P=0.006).
  • MSI-H was associated with higher age at diagnosis (r=0.24; P=0.04), antral location (r=0.252; P=0.04), intestinal type (P=0.044), expansive growth (P=0.001), tubular type (0.014), better differentiation (P=0.01), less nodal involvement (0.006) and better survival (P=0.022).
  • CONCLUSION: The experimental design presented in the study may be of potential value for clinicians: at least five relevant markers for both MSI and LOH analysis may be needed to evaluate a gastric cancer (GC) patient's clinical status.
  • [MeSH-major] Adenocarcinoma / genetics. Loss of Heterozygosity. Microsatellite Instability. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1038-40 [17998824.001]
  • (PMID = 17998833.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


66. Mărgăritescu C, Mogoantă L, Mănescu P, Simionescu C, Pirici D, Streba L, Mercuţ D: The immunohistochemical profile of the adenocarcinoma of upper gastric pole. Rom J Morphol Embryol; 2007;48(3):215-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemical profile of the adenocarcinoma of upper gastric pole.
  • Although gastric adenocarcinoma continue to be the second continues to be the second cause of death worldwide, its incidence and mortality appear to have decreased in recent decades.
  • Despite this decline, adenocarcinomas from proximal stomach tend to be more frequent during the last three decade.
  • Adenocarcinomas with this location it seems that are a different, specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences between gastric adenocarcinomas from upper and distal gastric pole using the immunohistochemistry.
  • For this reason, we investigate histopathological and immunohistochemically 77 cases of upper gastric pole adenocarcinoma selected from a number of 472 gastric tumors.
  • The acquired results do not distinguish a peculiar immunohistochemically profile unlike distal gastric adenocarcinomas.
  • Nevertheless, we pointed out the predominance of diffuse adenocarcinomas type according to Laurens classification, which immunohistochemically were strong positive to cytokeratins, EMA, CEA and lysozyme.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Esophagogastric Junction. Immunohistochemistry / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914488.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD34; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Keratin-7; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53; 0 / Vimentin; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


67. Rodríguez Ortega M, Carabias Hernández A, Rodríguez Barbero JM, Garaulet González P, Limones Esteban M: [Intestinal linitis plastica: late metastasis from gastric signet ring cell adenocarcinoma]. Cir Esp; 2006 Sep;80(3):171-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intestinal linitis plastica: late metastasis from gastric signet ring cell adenocarcinoma].
  • [Transliterated title] Linitis plástica intestinal: metástasis tardía de adenocarcinoma gástrico en anillo de sello.
  • Linitis plastica is a malignant disease that usually occurs in the stomach, although it can affect any segment of the alimentary tract.
  • We present the case of a patient with a previous diagnosis of signet ring cell cancer of the stomach that had been treated with curative intent 12 years before the clinical onset of small and large bowel linitis plastica.
  • The diagnosis was obtained as an incidental pathological finding after urgent surgery for intestinal obstruction.
  • No gastric mass was found.
  • Linitis plastica should be considered in the differential diagnosis of patients with symptoms of obstruction after resection of a gastric carcinoma, especially if there are macroscopic surgical findings of circumferential narrowing.
  • A long interval after diagnosis and treatment of the primary disease does not allow malignancy to be ruled out.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Intestinal Neoplasms / secondary. Linitis Plastica / secondary. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956554.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


68. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • The prognosis of locally advanced gastric cancer remains poor.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


69. Lee SH, Choi WC, Kim KS, Park JW, Lee SH, Yoon SW: Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med; 2010 Apr;16(4):497-500
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract.
  • PATIENT AND METHOD: We present here the case of a female patient (82 years old) with an adenocarcinoma of the stomach that was first diagnosed via an abdomen computed tomography (CT) scan and endoscopic biopsy.
  • CONCLUSIONS: We suggest that RVS extract could be a candidate for a natural agent that induces selective apoptosis and inhibits cell growth in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Flavonoids / therapeutic use. Phytotherapy. Plant Extracts / therapeutic use. Rhus. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423218.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Plant Extracts
  •  go-up   go-down


70. Calcagno DQ, Leal MF, Taken SS, Assumpção PP, Demachki S, Smith Mde A, Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4069-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma.
  • BACKGROUND: Gastric cancer is the third most frequent type of neoplasia.
  • MATERIALS AND METHODS: Dual-color fluorescence in situ hybridization (FISH) for the C-MYC gene and chromosome 8 centromere was performed in 11 gastric adenocarcinomas.
  • CONCLUSION: Chromosome 8 can be used as a marker in the diagnosis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jan-Feb;26(1a):445
  • (PMID = 16309200.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


71. Huang Q, Huang Q, Lin W, Lin J, Lin X: Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis. J Cancer Res Clin Oncol; 2010 Aug;136(8):1275-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
  • PURPOSE: This study aimed to investigate the expression level of human proteasome activator PA28beta subunit (PA28beta) in gastric adenocarcinomas (GA) tissues and investigate its potential role in GA carcinogenesis.
  • CONCLUSIONS: These results indicated that PA28beta might participate in the origin and progression of GA cancer through changes to cell proliferation activity and tumorigenicity.
  • [MeSH-major] Adenocarcinoma / genetics. Muscle Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140627.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Muscle Proteins; EC 3.4.25.1 / PSME2 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


72. Supriatna Y, Kishimoto T, Uno T, Nagai Y, Ishikura H: Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA. Pathology; 2005 Jun;37(3):211-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology: a study with in situ hybridisation for albumin mRNA.
  • AIM: Hepatoid adenocarcinoma, a putative chemosensitive tumour, is defined as a tumour with aberrant hepatocellular differentiation occurring in extrahepatic organs such as the stomach, usually in the gastrointestinal tract.
  • We investigated ALB mRNA to address whether adenocarcinoma with hepatoid morphology, regardless of AFP production, can be diagnosed solely by morphological criteria as a hepatoid adenocarcinoma.
  • METHODS: We performed in situ hybridisation (ISH) and immunohistochemistry (IH) for ALB mRNA on AFP-negative gastric adenocarcinomas with hepatoid morphology.
  • AFP-positive hepatoid adenocarcinomas and AFP-negative conventional gastric adenocarcinomas were also investigated as positive and negative controls, respectively.
  • RESULTS: All three gastric adenocarcinomas with hepatoid morphology with no evidence of AFP production stained positive for ALB mRNA, thus providing evidence of differentiation in the hepatocellular direction.
  • Three of five cases of AFP-positive hepatoid adenocarcinoma of the stomach were positive for ALB mRNA, while 11 cases of AFP-negative conventional gastric adenocarcinoma were negative.
  • CONCLUSION: The present study demonstrates that, irrespective of AFP production, gastric adenocarcinoma with morphological patterns suggestive of hepatoid differentiation should be diagnosed as hepatoid adenocarcinoma with important prognostic implications.
  • [MeSH-major] Adenocarcinoma / pathology. Albumins / biosynthesis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Stomach Neoplasms / pathology. alpha-Fetoproteins / biosynthesis
  • [MeSH-minor] Diagnosis, Differential. Hepatocytes / pathology. Humans. Immunohistochemistry. In Situ Hybridization. RNA, Messenger / analysis. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175893.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / alpha-Fetoproteins
  •  go-up   go-down


73. Tormo Ferrero V, Andreu Martínez FJ, Cardenal Macía R, Pomares Arias A: Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. Clin Transl Oncol; 2006 Aug;8(8):611-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer.
  • PURPOSE: In this study we evaluated the acute toxicity of the combined treatment with chemoradiotherapy, according to the scheme of McDonald et al, in patients diagnosed with gastric cancer, after radical curative surgery.
  • METHODS: From July 2001 to December 2005, a total of 24 patients, with diagnosis of adenocarcinoma of the stomach or adenocarcinoma of the gastroesophageal junction, who were operated with total or subtotal gastrectomy with free resection margins, were treated at our service with a combined scheme of adjuvant chemoradiotherapy.
  • CONCLUSIONS: Combined treatment with chemoradiotherapy, according to the scheme of Macdonald, in diagnosed patients with gastric cancer, after radical curative surgery is a well tolerated treatment, with a low degree of acute toxicity, thus the treatment compliance is not difficult.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952851.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


74. Namikawa T, Hanazaki K: Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma. World J Gastroenterol; 2010 Oct 7;16(37):4634-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma.
  • Differentiated adenocarcinoma of the stomach is classified into gastric or intestinal phenotypes based on mucus expression.
  • Recent advances in mucin histochemistry and immunohistochemistry have highlighted the importance of such a distinction, and it is important clinically to distinguish between gastric- and intestinal-type differentiated adenocarcinoma.
  • However, a clinical and pathological diagnosis of this type is often difficult in early gastric cancer because of histological similarities between a hyperplastic epithelium and low-grade atypia.
  • It is therefore critical to consider these diagnostic difficulties and different biological behaviors with high malignant potential when treating patients with gastric-type differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Mucins. Phenotype. Stomach Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2000 Jul;191(3):257-63 [10878546.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):724-32 [10951333.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1523-30 [11813565.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1223-34 [15154009.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Natl Cancer Inst. 1974 Jul;53(1):19-30 [4835098.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):498-503 [6190549.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gastric Cancer. 2005;8(4):220-7 [16328596.001]
  • [Cites] World J Gastroenterol. 2006 Apr 28;12(16):2510-6 [16688795.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6469-79 [17085661.001]
  • [Cites] J Pathol. 1993 Jan;169(1):73-8 [8433217.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):265-72 [8440743.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3179-84 [7902202.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):556-64 [8033033.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):455-64 [9247464.001]
  • (PMID = 20872962.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC2951512
  •  go-up   go-down


75. Alexander JS, Mathis JM, Pruitt K: Interaction of microsatellite instability and loss of heterozygosity in adenocarcinoma: multiple markers in adenocarcinoma: an introduction to 'Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA'. Eur J Gastroenterol Hepatol; 2007 Dec;19(12):1038-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction of microsatellite instability and loss of heterozygosity in adenocarcinoma: multiple markers in adenocarcinoma: an introduction to 'Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA'.
  • Gastric cancer is the second most frequent cause of cancer death worldwide, yet the precise mechanisms underlying the different subtypes of gastric carcinogenesis are poorly understood.
  • Improvements in the diagnosis and prognosis of gastric cancer over classical clinicopathologic findings such as TNM stage, age or macroscopic tumor type, now include novel techniques for superficial endoscopic examination, and new strategies for genetically analyzing biopsied specimens.
  • The development of gastric adenocarcinomas, such as that of many tumor classes, represents the cumulative effects of several different types of mutations, and it is now recognized that both the loss of normal DNA repair, as well as the mutation, loss or inhibition of tumor suppressor genes contribute to the genetic instability leading to cancer.
  • It might be logically anticipated that the combined burden of these two defects would synergize in carcinogenesis, but the extent to which such pathways cooperate in promoting cancer is still not yet well understood.
  • Clearly, an enhanced appreciation of the mechanisms and interactions of these pathways would aid development of diagnosis and treatment options.
  • [MeSH-major] Adenocarcinoma / genetics. Loss of Heterozygosity. Microsatellite Instability. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1082-9 [17998833.001]
  • (PMID = 17998824.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  • [Number-of-references] 14
  •  go-up   go-down


76. Monari M, Trinchero A, Calabrese C, Cattani O, Serrazanetti GP, Foschi J, Fabbri A, Zahlane D, Di Febo G, Tonini V, Cervellera M, Tosi MR, Tugnoli V: Superoxide dismutase in gastric adenocarcinoma: is it a clinical biomarker in the development of cancer? Biomarkers; 2006 Nov-Dec;11(6):574-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superoxide dismutase in gastric adenocarcinoma: is it a clinical biomarker in the development of cancer?
  • Gastric cancer is the second most common cancer worldwide.
  • The involvement of reactive oxygen species (ROS) in the pathogenesis of gastric malignancies is well known.
  • The aim of this study is the detection of MnSOD and CuZnSOD activity and their expression in gastric adenocarcinoma and healthy tissues.
  • Gastric samples (adenocarcinoma and healthy tissues) harvested during endoscopy or resected during surgery were used to determine MnSOD and CuZnSOD activity and expression by spectrophotometric and Western blotting assays.
  • The total SOD activity was significantly higher (p<0.05) in healthy mucosa with respect to gastric adenocarcinomas.
  • No differences were found in MnSOD activity and, on the contrary, CuZnSOD activity was significantly lower (p<0.001) in cancer samples with respect to normal mucosa.
  • The rate of MnSOD/CuZnSOD activity in adenocarcinoma was over ninefold higher than that registered in healthy tissues (p<0.05).
  • Moreover, in adenocarcinoma MnSOD activity represented the 83% of total SOD with respect to healthy tissues where the ratio was 52% (p<0.001).
  • On the contrary, in cancer tissues, CuZnSOD activity accounted for only 17% of the total SOD (p<0.001 if compared with the values recorded in normal mucosa).
  • After immunoblotting, MnSOD was more expressed in adenocarcinoma with respect to normal mucosa (p<0.001), while CuZnSOD was similarly expressed in adenocarcinoma and healthy tissues.
  • [MeSH-major] Gastric Mucosa / enzymology. Stomach Neoplasms / diagnosis. Superoxide Dismutase / analysis
  • [MeSH-minor] Adenocarcinoma. Biomarkers, Tumor. Blotting, Western. Case-Control Studies. Humans. Kinetics. Spectrum Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056476.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


77. Doggui MH, Ben Yaghlène L, Hefaiedh R, Bouguassas W, Mestiri A, Dellagi K: A gastric collision tumor composed of adenocarcinoma and gastrinoma: case report. Tunis Med; 2008 Aug;86(8):755-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gastric collision tumor composed of adenocarcinoma and gastrinoma: case report.
  • BACKGROUND: Collision tumors of the stomach are exceedingly rare, with only six previous reported instance in which adenocarcinoma of the stomach were found in association with carcinoid tumor.
  • Only in one case the adenocarcinoma was associated with a gastrinoma.
  • AIM: we report the second case of Collision tumor between adenocarcinoma and gastrinoma.
  • OBSERVATION: A 55 years old man was admitted in our department for an exploration of gastric pain with rapid weight loss.
  • Upper endoscopy showed in the fundic region of the stomach an exophytic process wildly ulcerative in his center associated with the presence of a multiple polypoid tumors.
  • The pathologic examination of the biopsy specimen of the process revealed an adenocarcinoma and of the polypoid tumors showed a carcinoid type tumor.
  • The biopsies of the non tumoral gastric mucosa were normal.
  • The diagnosis of collision type tumors between adenocarcinoma and gastrinoma was retained.
  • CONCLUSION: Through this observation and with a review of literature, the coexistence of adenocarcinoma and carcinoid tumor of the stomach is discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrinoma / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472762.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


78. Doroshow JH, McCoy S, Macdonald JS, Issell BF, Patel T, Cobb PW, Yost KJ, Abbruzzese JL: Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. Invest New Drugs; 2006 Nov;24(6):537-42
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
  • From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832602.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76462
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PN 401; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; WHI7HQ7H85 / Uridine
  •  go-up   go-down


79. Zhang S, Wang M, Xue YH, Chen YP: Cerebral metastasis from hepatoid adenocarcinoma of the stomach. World J Gastroenterol; 2007 Nov 21;13(43):5787-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral metastasis from hepatoid adenocarcinoma of the stomach.
  • We first report a rare case of metastasis from gastric hepatoid adenocarcinoma (HAC) to cerebral parenchyma, in a 50-year-old Chinese patient.
  • Three years ago, the patient accepted total gastrectomy as he was pathologically diagnosed at gastroscopy having an adenocarcinoma.
  • Histopathological characteristics of the brain tumor were identical to those of stomach tumor.
  • The differential diagnosis of brain metastasis from metastatic tumors should use a panel of antibodies to avoid confusing with the brain metastasis of hepatocellular carcinoma (HCC).
  • This paper describes this rare case of metastasis from gastric hepatoid adenocarcinoma to cerebral parenchyma, and provides a review of the literature concerning its histopathological and immunohistochemical characteristics.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963312.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4171272
  •  go-up   go-down


80. Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M: Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol; 2006 Apr 28;12(16):2510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.
  • AIM: Minimal deviation carcinoma of the uterine cervix, otherwise known as extremely well-differentiated adenocarcinoma (EWDA), is characterized by its benign microscopic appearance in contrast to its aggressive behavior.
  • In order to elucidate the clinicopathological features and biological behavior of the gastric counterpart of EWDA, we, using immunohistochemistry, analyzed nine lesions for the phenotypic expression, proliferative activity, and the expression of oncogene-associated products.
  • METHODS: Clinicopathological features, including pre-operative biopsy diagnosis, were reviewed.
  • Using immunohistochemistry, Ki-67 labeling index and expression of p53 and c-erbB-2 protein in the gastric lesions were detected.
  • RESULT: Locations in the middle or upper third of the stomach and polypoid macroscopic features are characteristic of EWDA of the stomach.
  • All 9 cases of EWDA could be classified into gastric phenotype (5 lesions) and intestinal phenotype (4 lesions).
  • The former resembled gastric foveolar epithelium, mucous neck cells or pyloric glands, but their papillary structures were frequently elongated and the tumor cells and their nuclei were slightly larger and more hyperchromatic compared to normal epithelium.
  • CONCLUSION: Unlike minimal deviation carcinoma of the cervix, these findings suggest that EWDA of the stomach is a lesion of low-grade malignancy.
  • Because of its resemblance to normal gastric mucosa or mucosa with intestinal metaplasia, EWDA is often misdiagnosed.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Apr;91(4):839-48 [7513368.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):511-7 [8129036.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1161-6 [8813081.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):867-70 [9625834.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1719-29 [10223565.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):104-6 [10393360.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):279-87 [10746668.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):713-8 [10854531.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):869-73 [12064010.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Br J Cancer. 1980 Feb;41(2):209-21 [6989383.001]
  • [Cites] Biochem J. 1980 Nov 1;191(2):645-8 [7016112.001]
  • [Cites] J Exp Med. 1981 Oct 1;154(4):1249-54 [6945392.001]
  • [Cites] Acta Pathol Jpn. 1983 Mar;33(2):395-401 [6869006.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):304-10 [1988372.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5879-85 [7680650.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • (PMID = 16688795.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MUC6 protein, human; 0 / Mucin-6; 0 / Mucins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4087982
  •  go-up   go-down


81. Belhaj A, Memmo L, Mehdi A, Mboti F, Closset J: [Gastric adenocarcinoma following "silastic vertical ring gastroplasty": case report]. Rev Med Brux; 2010 Sep-Oct;31(5):459-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma following "silastic vertical ring gastroplasty": case report].
  • [Transliterated title] Survenue d'un adénocarcinome gastrique 10 ans après une "silastic ring vertical gastroplasty ": cas isolé ou lien de cause à effet?
  • And, it remains unclear if the late occurrence of gastric adenocarcinoma could be linked to bariatric surgery.
  • We described a case of a female who developed a gastric adenocarcinoma after a silastic ring vertical gastroplasty (SRVG).
  • A gastroscopy with biopsy disclosed a juxta-pyloric adenocarcinoma.
  • The pathological studies demonstrated a T2bN1 adenocarcinoma with negative margins.
  • CONCLUSION: The association between a gastric adenocarcinoma and a bariatric procedure such as a SRVG is difficult to assess without a case-control or a cross-sectional study.
  • Nevertheless, when new upper digestive tract complaints occur in any patient with an otherwise unremarkable bariatric surgery follow-up, the diagnosis of gastric cancer should be bear in mind.
  • [MeSH-major] Adenocarcinoma / etiology. Gastroplasty / adverse effects. Stomach Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Med Brux. 2010 Nov-Dec;31(6):556. Memo, L [corrected to Memmo, L]
  • (PMID = 21174648.001).
  • [ISSN] 0035-3639
  • [Journal-full-title] Revue médicale de Bruxelles
  • [ISO-abbreviation] Rev Med Brux
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  •  go-up   go-down


82. Ghosh P, Miyai K, Chojkier M: Gastric adenocarcinoma inducing portal hypertension: a rare presentation. World J Gastroenterol; 2007 Feb 14;13(6):960-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma inducing portal hypertension: a rare presentation.
  • Advanced gastric cancer usually presents with symptoms due to direct extension into adjacent viscera, distant metastases from lymphatic or hematogenic dissemination and peritoneal seeding.
  • However, portal hypertension as a presentation of metastatic gastric cancer is rare and usually seen in association with other malignancies, e.g. hepatocellular and pancreatic carcinoma.
  • We report a case of signet ring adenocarcinoma of the stomach that presented with esophageal and duodenal varices and bleeding due to portal hypertensive gastropathy.
  • Pagetoid spread of cancer cells likely caused early metastasis and the unusual presentation.
  • [MeSH-major] Adenocarcinoma / complications. Hypertension, Portal / etiology. Stomach Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Gastrointestinal Hemorrhage / diagnosis. Gastrointestinal Hemorrhage / etiology. Humans. Male. Stomach / pathology. Stomach / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Portal hypertension.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Assoc Physicians India. 1999 Jul;47(7):730-2 [10778598.001]
  • [Cites] Int J Clin Pract. 2005 Jan;59(1):119-20 [15707476.001]
  • [Cites] J Clin Gastroenterol. 2001 May-Jun;32(5):444-7 [11319321.001]
  • [Cites] Br J Radiol. 2001 Jul;74(883):654-6 [11509404.001]
  • [Cites] J Gastroenterol. 2002;37(3):220-8 [11931537.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):165-70 [12714889.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] J Gastroenterol. 2003;38(12):1176-80 [14714257.001]
  • [Cites] An Med Interna. 2004 Jun;21(6):283-4 [15283642.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):811-4 [1689502.001]
  • [Cites] Postgrad Med J. 1990 May;66(775):401-3 [2371194.001]
  • [Cites] Jpn J Surg. 1991 Sep;21(5):583-6 [1813699.001]
  • [Cites] Am J Gastroenterol. 1993 Nov;88(11):1942-5 [8237946.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):529-33 [7550867.001]
  • [Cites] Tohoku J Exp Med. 1998 Oct;186(2):121-30 [10223615.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):67-71 [15293065.001]
  • [Cites] Yale J Biol Med. 1999 Jul-Aug;72(4):295-300 [10907780.001]
  • (PMID = 17352032.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4065938
  •  go-up   go-down


83. Lin CW, Hsu CC, Chang HC, Sun YC, Sun PL, Hsu CY, Perng DS: Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report. Cases J; 2009;2:6317

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report.
  • INTRODUCTION: Hepatoid adenocarcinoma is a special type of extrahepatic alpha-fetoprotein-producing adenocarcinoma, which has a morphologic similarity to hepatocellular carcinoma.
  • We report a patient with underlying hepatitis B virus infection and hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma.
  • Moreover, the subsequent endoscopy revealed gastric tumor.
  • However, the tumor histology of the stomach and liver revealed glandular adenocarcinoma with hepatoid foci.
  • The final diagnosis is hepatoid adenocarcinoma of the stomach with liver metastasis.
  • CONCLUSION: Hepatoid adenocarcinoma is an aggressive tumor with liver metastasis being the first clinical manifestation of the neoplasm.
  • Hepatoid adenocarcinoma of the stomach with liver metastasis should be considered in older patients with elevated serum alpha-fetoprotein and multiple hepatic tumors with underlying chronic liver disease.
  • An upper gastrointestinal endoscopy should be performed to exclude the possibility of hepatoid adenocarcinoma originating from the stomach to avoid potential misdiagnosis and inappropriate therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Presse Med. 1970 Jun 6;78(28):1277-8 [5426134.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2165-73 [6091861.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1827-35 [7689918.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Histopathology. 1997 Jul;31(1):47-54 [9253624.001]
  • [Cites] Mayo Clin Proc. 1997 Dec;72(12):1154-60 [9413299.001]
  • [Cites] Hepatology. 2000 Aug;32(2):200-4 [10915724.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1302-12 [14508391.001]
  • [Cites] Pathology. 2005 Jun;37(3):211-5 [16175893.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jul-Sep;69(3):330-7 [17168134.001]
  • [Cites] J Dig Dis. 2007 Feb;8(1):23-8 [17261131.001]
  • (PMID = 19918575.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769285
  •  go-up   go-down


84. Sentani K, Oue N, Sakamoto N, Arihiro K, Aoyagi K, Sasaki H, Yasui W: Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Mod Pathol; 2008 Apr;21(4):464-75
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach.
  • Gastric cancer is one of the most common malignancies worldwide.
  • In this study, we screened for genes upregulated in gastric cancer by comparing gene expression profiles from serial analysis of gene expression and microarray and identified the palate, lung, and nasal epithelium carcinoma-associated protein (PLUNC) gene.
  • Immunostaining for PLUNC in 140 gastric cancer cases revealed strong and extensive staining of PLUNC in hepatoid adenocarcinoma of the stomach, whereas 7% of conventional gastric cancer cases showed focal immunostaining of PLUNC.
  • Gastric hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphologic similarities to hepatocellular carcinoma.
  • To investigate the utility of PLUNC immunostaining in the diagnosis of gastric hepatoid adenocarcinoma, six cases of gastric hepatoid adenocarcinoma (six primary tumors and two associated liver metastases) were studied further.
  • PLUNC staining was observed in all six primary hepatoid adenocarcinomas.
  • PLUNC staining was observed in both the hepatoid adenocarcinoma and tubular/papillary adenocarcinoma components of primary tumors, although PLUNC staining was preferentially localized in tubular/papillary adenocarcinoma components.
  • These results indicate that PLUNC is a novel marker that distinguishes gastric hepatoid adenocarcinoma from primary hepatocellular carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Glycoproteins / biosynthesis. Oligonucleotide Array Sequence Analysis. Phosphoproteins / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / metabolism. Diagnosis, Differential. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204429.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Phosphoproteins
  •  go-up   go-down


85. Schneider S, Krikmann U, Lüüs SM, Kulla A, Haldre S: Neoplastic meningitis as the presenting manifestation of gastric adenocarcinoma. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis as the presenting manifestation of gastric adenocarcinoma.
  • The aetiology of the chronic meningitis was revealed gastric cancer by gastroscopy, and micrometastasis by bone marrow trephine biopsy.
  • Autopsy confirmed the presence of advanced gastric cancer (adenocarcinoma of signet-ring cell type) with pancreatic involvement, and NM with cancer cells on the meninges, but without infiltration tumour cells into underlying brain parenchyma.
  • We conclude that NM as an initial symptom of gastric cancer is rare and ultimately fatal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3):312-23 [16769420.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):517-27 [12057097.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):225-35 [11937001.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] Lancet Neurol. 2006 May;5(5):443-52 [16632315.001]
  • (PMID = 21785656.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029123
  •  go-up   go-down


86. Khosravi Shahi P, Díaz Muñoz de la Espada VM, García Alfonso P, Encina García S, Izarzugaza Perón Y, Arranz Cozar JL, Hernández Marín B, Pérez Manga G: Management of gastric adenocarcinoma. Clin Transl Oncol; 2007 Jul;9(7):438-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gastric adenocarcinoma.
  • Gastric adenocarcinoma is the second most common cause of cancer death worldwide.
  • The prognosis for patients with gastric adenocarcinoma depends on the stage of the disease at the time of diagnosis and treatment.
  • Early gastric cancer, limited to the mucosa and submucosa, is best treated surgically and has a five-year survival rate of 70-95%.
  • The management of localised gastric adenocarcinoma is complex, and at present there is proven benefit of both preoperative chemotherapy and postoperative chemoradiotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652057.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic
  • [Number-of-references] 41
  •  go-up   go-down


87. Lee DH, Park JH, Kim HJ, Lim JW, Ko YT: Exophytic adenocarcinoma of the stomach: computed tomography and ultrasonography features with emphasis on differentiation from a malignant gastrointestinal stromal tumor. Clin Imaging; 2008 Nov-Dec;32(6):447-52
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic adenocarcinoma of the stomach: computed tomography and ultrasonography features with emphasis on differentiation from a malignant gastrointestinal stromal tumor.
  • The purpose of this study was to assess the computed tomography (CT) and ultrasonography (US) findings from cases of exophytic adenocarcinoma of the stomach (EAS) and to determine their value in distinguishing between an EAS and a malignant gastrointestinal stromal tumor (MST).
  • Antral location, thickening of the gastric wall adjacent to an exogastric mass, lymph node enlargement, and discordant images between US and CT are typical of EAS cases and allow distinction between cases of EAS and MST.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Stomach Neoplasms / diagnosis. Tomography, X-Ray Computed / methods. Ultrasonography / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006773.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Kishino M, Hamab Y, Furukawa S: Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):e49-53
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma.
  • A case of metastatic adenocarcinoma from gastric cancer to the mandibular canine region is reported.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Mandibular Neoplasms / secondary. Osteolysis / radiography. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464643.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal MF, Guimarães AC, Calcagno DQ, Khayat AS, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR: Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. Cancer Genet Cytogenet; 2008 Feb;181(1):31-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma.
  • Gastric cancer is the second leading cause of death by cancer in Brazil.
  • Early gastric cancer represents approximately 10% of gastric cancer cases in some services of Brazil, which underscores the need for early gastric cancer diagnosis that could lead to better prognosis.
  • There are few published studies of cytogenetic alterations in early gastric cancer.
  • To evaluate MYC copy number and its protein expression, we performed fluorescence in situ hybridization and immunohistochemical analyses in five early gastric adenocarcinomas in individuals from northern Brazil.
  • These novel findings concerning MYC copy number alteration in early gastric cancer suggest that MYC alteration is observed in the beginning of gastric carcinogenesis and could be used as a therapeutic target.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262050.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Ychou M, Gory-Delabaere G, Blanc P, Bosquet L, Duffour J, Giovannini M, Guillemin F, Lemanski C, Marchal F, Masson B, Merrouche Y, Monges G, Adenis A, Bosset JF, Bouché O, Conroy T, Pezet D, Triboulet JP, Fédération nationale des centres de lutte contre le cancer (FNCLCC), Fédération hospitalière de France (FHF), Fédération nationale de Cancérologie des CHRU (FNCHRU), Fédération française de cancérologie des CHG (FFCCHG), Centres régionaux de lutte contre le cancer (CRLCC): [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)]. Bull Cancer; 2005 Apr;92(4):381-409
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical Practice Guidelines 2004. Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach: radiotherapy (therapeutic evaluation)].
  • [Transliterated title] Recommandations pour la pratique clinique. Standards, Options et Recommandations 2004 pour la prise en charge des patients atteints d'adénocarcinomes de l'estomac, cancers du cardia, autres types histologiques exclus (évaluation des thérapeutiques).
  • CONTEXT: The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of French Cancer Centers (FNCLCC), the 20 French regional cancer centers, and specialists from French Public Universities, General Hospitals and Private Clinics.
  • The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients.
  • OBJECTIVES: To elaborate clinical practice guidelines for patients with stomach adenocarcinoma.
  • These recommendations cover the diagnosis, treatment and follow-up of these tumors.
  • METHODS: The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888395.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 192
  •  go-up   go-down


91. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • The diagnosis of gastric epithelial dysplasia, a precursor lesion of gastric adenocarcinoma, is hindered by interobserver variability and by its resemblance to regenerative changes.
  • Loss of cell polarity, a histological feature of gastric epithelial dysplasia, may be difficult to ascertain, especially in the setting of inflammation or injury.
  • A biomarker of cell polarity could be useful in diagnosis of dysplasia, but has not been reported.
  • Two homologs, lgl1 and lgl2, are present in mammals and lgl2 mRNA is highly expressed in the stomach.
  • The goal of our study was to test the hypothesis that Lgl2 protein expression and/or localization are disrupted in gastric epithelial dysplasia and adenocarcinoma.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • All normal, reactive, and chronically inflamed gastric epithelia showed basolateral Lgl2 staining.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • All but one case each of gastric epithelial dysplasia and adenocarcinoma showed either complete loss of anti-Lgl2 immunoreactivity or diffuse, mostly weak, cytoplasmic staining.
  • Complete loss of immunoreactivity was significantly more often observed in diffuse-type than in intestinal-type adenocarcinomas (79 vs 48%, respectively).
  • Our data suggest that Lgl2 expression is either aberrantly localized or lost in gastric epithelial dysplasia and adenocarcinoma, whereas it is maintained in reactive gastric mucosa.
  • We propose that Lgl2 may be a potential marker to rule out gastric epithelial dysplasia and adenocarcinoma in diagnostic specimens.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


92. Smith BR, Stabile BE: Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy. J Gastrointest Surg; 2007 Feb;11(2):127-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy.
  • National trends indicate a longstanding decline in gastric adenocarcinoma due presumably to a decreasing prevalence of Helicobacter pylori infection.
  • We hypothesize that recent immigration patterns are responsible for a leveling off or even reversal of the declining incidence of gastric cancer associated with H. pylori infection.
  • A retrospective review of a consecutive case series at a public teaching hospital located in an area of high immigration was conducted that included all patients presenting, from 1995 through 2004, with gastric adenocarcinoma.
  • There was no decline in the frequency of gastric adenocarcinoma among the study population over the 10 years.
  • The operation rate decreased and the gastric resection rate increased from the early period to the recent period as fewer incurable advanced stage (M1) patients underwent exploratory laparotomy and were palliated by nonoperative means.
  • We conclude that in an area of high immigration there has been no decline in gastric adenocarcinoma rates over the past decade, and the marked reduction in perioperative mortality was due to near elimination of nontherapeutic laparotomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Laparotomy / mortality. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390160.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Song SY, Son HJ, Kim MH, Nam ES, Rhee JC, Park C: Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology; 2007 Apr-May;54(75):973-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of maspin expression in human gastric adenocarcinoma.
  • However, molecular aspects in carcinogenesis and progression of gastric cancer remain largely unclear.
  • Previously we reported for the first time that maspin is induced in the course of gastric carcinogenesis.
  • In the present study we evaluated maspin induction in gastric adenocarcinoma in relation to a number of clinicopathologic feature.
  • METHODOLOGY: Maspin expression was examined by Western blot analysis and immunohistochemical staining in 82 cases of gastric adenocarcinoma.
  • RESULTS: In Western blot analysis, gastric specimens of tumor showed increased maspin expression compared with corresponding normal tissues in 54 of 82 patients (66%).
  • The frequency of maspin induction was associated with the stage of gastric cancer (p = 0.01) and lymph node metastasis (p = 0.03).
  • CONCLUSIONS: Our data suggest that maspin may have an important role in the progression and metastasis of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Serpins / analysis. Serpins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Blotting, Western. Female. Helicobacter Infections / diagnosis. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591106.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


94. Huang Q, Huang Q, Chen W, Wang L, Lin W, Lin J, Lin X: Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J Cancer Res Clin Oncol; 2008 Nov;134(11):1219-27
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology.
  • PURPOSE: To find a biomarker for gastric adenocarcinomas (GA).
  • Forty-two protein spots that were differentially expressed by twofold or greater between cancer and normal mucosa tissue were excised and identified by MALDI-TOF/TOF MS.
  • Expression of 29 of these proteins was decreased (ratio >or= 2, P < 0.01), including adenosine deaminase; and 13 proteins displayed over-expression in cancer tissue (ratio >or= 2, P < 0.01), including transgelin.
  • The results of immunohistochemistry confirmed that transgelin was indeed over-expressed in 22 cases of GA (22/41, 53.66%), with strong cytoplasmic staining in cancer cells of positive samples, this was absent in most paired non-neoplastic mucosa cells or gastric ulcer tissues (n = 20).
  • Transgelin was found over-expressed in 21 samples of cancer tissue (21/41, 51.22%) when detected by western blot.
  • [MeSH-major] Adenocarcinoma / diagnosis. Microfilament Proteins / metabolism. Muscle Proteins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Electrophoresis, Gel, Two-Dimensional. Female. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Isoelectric Focusing. Male. Middle Aged. Neoplasm Staging. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18446369.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / transgelin
  •  go-up   go-down


95. Zhang Y, Ye X, Geng J, Chen L: Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in gastric and colorectal adenocarcinoma. Hepatogastroenterology; 2010 Nov-Dec;57(104):1614-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in gastric and colorectal adenocarcinoma.
  • BACKGROUND/AIM: Deleted in Lung and Esophageal Cancer 1 (DLEC1) gene was a new candidate tumor suppressor gene, we evaluated the diagnostic role of DLEC1 methylation in gastric adenocarcinoma (GAC) and colorectal adenocarcinoma (CRAC).
  • RESULTS: DLEC1 methylation was detected in 38.5% (25/65) of GAC and 45.1% (32/71) of CRAC tissues, while seldom in the adjacent normal tissues of stomach (8.0%, 4/50) and colorectum (7.1%, 4/56) (p < 0.001).
  • Moreover, 33.8% (22/65) of GAC and 39.4% (28/71) of CRAC serums had DLEC1 methylation, which was higher than that in the serums of cancer-free controls (p < 0.001), and the concordance of DLEC1 methylation in tumor tissues and corresponding serum samples was well.
  • CONCLUSION: Epigenetic inactivation of DLEC1 was crucial in gastric and colorectal carcinogenesis.
  • DLEC1 methylation in serum may be a promise biomarker for GAC and CRAC early diagnosis.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics


96. Simonenko VB, Vasil'chenko MI, Zykov DV, Lesovik VS, Makanin MA, Dulin PA: [Poorly differentiated stomach adenocarcinoma combined with jejunal stromal tumour. Clinical study]. Klin Med (Mosk); 2009;87(10):73-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Poorly differentiated stomach adenocarcinoma combined with jejunal stromal tumour. Clinical study].
  • A rare clinical case of GIST measuring 1.2 CM with concomitant stomach cancer (poorly differentiated carcinoma) is reported.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Jejunal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endoscopy, Gastrointestinal. Gastrectomy / methods. Humans. Laparotomy. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017358.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


97. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, Asmar L: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol; 2008 Jan;19(1):104-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND: Platinum-based chemotherapy is the standard treatment for advanced gastric cancer (GC).
  • PATIENTS AND METHODS: Patients with untreated stage IV GC or adenocarcinoma of the gastroesophageal junction (AGEJ) received docetaxel 60 mg/m(2) followed by oxaliplatin 130 mg/m(2) on day 1 of each 21-day cycle until progression or unacceptable toxicity.
  • RESULTS: Baseline characteristics (N = 71): median age 59 years, 72% male, 51% esophagogastric junction cancer, and Eastern Cooperative Oncology Group performance status of zero, one, two were 42%, 51%, 7%, respectively.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897959.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7487-88-9 / Magnesium Sulfate; 7S5I7G3JQL / Dexamethasone; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


98. Smith BR, Stabile BE: Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg; 2009 Jun;144(6):506-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young.
  • OBJECTIVE: To determine whether very young patients with gastric adenocarcinoma as compared with older patients with the disease have a biologically more aggressive form of the disease, presenting at an advanced stage and conferring unusually poor perioperative and long-term outcomes.
  • DESIGN, SETTING, AND PATIENTS: A 15-year, single-institution, retrospective review and analysis of demographic and outcomes data for 350 patients diagnosed with gastric adenocarcinoma.
  • MAIN OUTCOME MEASURES: Histologic features, frequency of stage IV disease, frequency of curative gastric resection, postoperative mortality, and long-term survival in very young and older patient groups.
  • CONCLUSIONS: Very young patients (aged < or = 35 years) with gastric adenocarcinoma have significantly higher incidences of diffuse-type tumor histologic findings and both locally advanced and metastatic disease at presentation.
  • Strategies for earlier diagnosis together with effective new therapies are desperately needed to attenuate the extreme lethality in these uniquely unfortunate patients.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528381.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Yang RC, Mills PK, Riordan DG: Gastric adenocarcinoma among Hmong in California, USA, 1988-2000. Gastric Cancer; 2005;8(2):117-23
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma among Hmong in California, USA, 1988-2000.
  • BACKGROUND: This study examined gastric adenocarcinoma incidence, mortality, and tumor characteristics in the Hmong population of California, 1988-2000.
  • Hmong are wary of Western medicine and would resort to it as the last option, which may delay the diagnosis and treatment of diseases such as cancer.
  • METHODS: Data from the California Cancer Registry were used to calculate incidence and mortality rates for Hmong, and were compared to these in Asian Pacific Islanders (API) and non-Hispanic whites (NHW).
  • RESULTS: Hmong experienced incidence and mortality rates of gastric adenocarcinoma several times higher than those of API and NHW.
  • Hmong were more likely to be diagnosed with cancer at later stages but at better histologic grades than API and NHW.
  • CONCLUSIONS: Further investigations into Helicobacter pylori, Epstein-Barr virus, acid reflux, and dietary practices of Hmong living in the United States are needed before any firm conclusion can be made, as these risk factors may impact gastric cancer development.
  • [MeSH-major] Adenocarcinoma / ethnology. Registries / statistics & numerical data. Stomach Neoplasms / ethnology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864719.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


100. Duan L, Wu AH, Sullivan-Halley J, Bernstein L: Passive smoking and risk of oesophageal and gastric adenocarcinomas. Br J Cancer; 2009 May 5;100(9):1483-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Passive smoking and risk of oesophageal and gastric adenocarcinomas.
  • Few studies have examined the association between passive smoking and the risk of oesophageal and gastric adenocarcinomas.
  • In a population-based case-control study with 2474 participants in Los Angeles County, there was no evidence that passive smoking had any appreciable effect on oesophageal or gastric adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1999 Oct;28(5):824-8 [10597977.001]
  • [Cites] Prev Med. 1984 Nov;13(6):680-90 [6536942.001]
  • [Cites] Am J Public Health. 1989 Feb;79(2):163-7 [2913834.001]
  • [Cites] Gut. 1998 Oct;43(4):537-41 [9824582.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):871-6 [10362132.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):461-8 [10473971.001]
  • [Cites] Alcohol. 2005 Apr;35(3):259-64 [16054988.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):689-701 [18293090.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Aug;12(8):837-42 [10958210.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):797-802 [11714107.001]
  • [Cites] Eur J Cancer Prev. 2002 Feb;11(1):27-38 [11917206.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438 [15285078.001]
  • [Cites] Free Radic Biol Med. 2000 Apr 1;28(7):1125-31 [10832074.001]
  • (PMID = 19352383.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES007048; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CN / N01CN25403; United States / NCI NIH HHS / CA / N01 CN025403; United States / NIEHS NIH HHS / ES / 5P30 ES07048
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Other-IDs] NLM/ PMC2694436
  •  go-up   go-down






Advertisement